Inflammatory
Clavis Pharma has synthesised and obtained promising data and patent protection on anti-inflammatory LVT-derivatives
based on well-known and widely prescribed anti-inflammatory agents.
Partners will be sought to develop these drug candidates and technologies.
Virology
Within the anti-viral market, Clavis Pharma's anti-viral drug candidates target the herpes and hepatitis segments where
there are considerable unmet needs.
The Company expects to begin to identify partners for the development of its drug candidates and LVT technology in the field of viral diseases as soon as possible.